Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

Hindsight 20/20: Jon H. Hoem

Hindsight 20/20 is a Q&A feature where medtech industry veterans share their long experience taking diverse businesses – be they start-ups or publicly-listed entities – from strength to strength and navigating through times of crises. In this installment, Jon H. Hoem, whose career in the cardiology sector spans more than two decades, explains how his thinking on building a robust clinical strategy has changed; why he believes you should never skimp on hiring talent; and advises on the difficult patches start-ups might hit and how to navigate around them, among other topics.

Commercial Business Strategies Hindsight 20/20
Advertisement

Companies

Set Alert for Companies

Latest From Companies

Novacyt Raises €9.7M, Ahead Of UK IPO

Clinical diagnostics firm Novacyt has raised €9.7M from UK and French investors ahead of plans to dual list on the London Stock Exchange Alternative Investment Market (AIM). The Cambridge, UK-based company is currently listed on the Euronext Growth Paris exchange.

Diagnostics In Vitro Diagnostics

Medovex Plans US IDE Trial For Its DenerveX Spine Surgery Device

DenerveX is a unique surgical tool used to ablate the nerve and capsular tissue on the posterior surface of the facet joint. preventing the nerve from reattaching with the goal of creating lasting relief from back pain that otherwise might require spinal fusion and/or treatment with opiate drugs.

Companies Innovation

Change At Helm As Tissue Regenix Enters Next Growth Phase

Regenerative medicine firm Tissue Regenix is now seeking a new CEO following the departure of Anthony Odell. The change in leadership comes two months after the company made its maiden M&A deal, acquiring CellRight Technologies.

Regenerative Medicine Companies
See All

Deals and Financings

Set Alert for Deals

Latest From Deals

M&A Analysis: Steady Goes September

Medtech M&A deal making has resumed the pace of activity seen before the brief surge in the summer. 17 M&A deals were announced and recorded on the Medtech Insight M&A deal tracker, one more than the previous month but included a few billion dollar transactions.

M & A Deals

Angle's Maiden M&A Fills Gaps In Liquid Biopsy Solution

By acquiring Axela Inc, liquid biopsy specialist Angle PLC will now be able to pair the Canadian firm's gene expression measurement technology with its Parsortix circulating tumor cell harvesting system. Angle will finance this transaction with the proceeds it expects to raise from a proposed £12.2m share placement.

Cancer In Vitro Diagnostics

VC Deals Analysis: Quarter-Billion Round Hikes September Takings To Five-Year High

September benefitted from two nine-figure venture financing rounds, including a $250m round by consumer genetic test service provider 23andme. These bumper deals significantly boost the total takings in 2017 so far to the extent that the year looks likely to beat 2016.

Deals Financing
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Industry Asks CMS To Allow More Medtech Input, Longer-Term Metrics In Bundled Pay Models

Industry groups told the US Medicare agency it should seek the input of a broader array of stakeholders – including medtech companies – in developing future episode-of-care pay models. They also argued that participation in the programs should be voluntary, and that the pay models should account for patient outcomes longer than 90 days following initial care. The responses came in comments to CMS following its proposal to scale back its joint replacement bundled payments program and eliminate a cardiac-care version.

Reimbursement Market Access

UK IVD Industry Finds New Voice And Appetite For Challenges Ahead

The association of the IVD industry in the UK, BIVDA, is undergoing a rebrand and proactively positioning itself to reinforce the value proposition that diagnostics represent for stakeholders. A new whitepaper on the theme was one of the highlights of an upbeat 2017 annual general meeting, in which Brexit and the EU IVDR for once were not the "stars" of the show.

United Kingdom In Vitro Diagnostics

Trump Rollback Of ACA Birth-Control Coverage Mandate To Push Down Gains In IUD Sales

More religious-based college employers, and for-profit businesses with moral objections to contraceptive coverage, will be able to issue health plans denying intrauterine device and birth control coverage to their employees and students starting in 2018, under the administration's Oct. 6-issued "conscience rights" exemptions from Affordable Care Act (ACA) requirements. The interim final rules could dampen sales of IUDs and implants that have risen 5% in the last year at Bayer Healthcare and Allergan.

Gynecology & Urology Market Access
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

From AI-Based IVDs To Precision Drug Dosing: Medtech Conference 2017 Gives Insight Into Tomorrow's Technologies

The annual AdvaMed conference, rebranded "Medtech Conference" this year, drew more than 2,700 attendees seeking to explore cutting-edge technologies and networking opportunities, as well as to hear from FDA's top officials about new developments. This article takes a closer look at some of the most innovative solutions presented at the event, including machine learning-based diagnostics to combat antimicrobial resistance, a ureter-locating device, virtual reality technologies to enhance orthopedic surgery and precision drug dosing, among other things.

StartUps and SMEs Innovation

Increasingly Less-Invasive Diagnostic Techs To Disrupt Interventional Cardio Market

The global market for diagnostic and guided interventional cardiology products is expected to reach $4.8bn by 2021, and is driven in large part by the rising elderly population and increasing burden of cardiovascular disease (CVD). Meddevicetracker expects that intracardiac echocardiography (ICE), guide wire-based intravascular stenosis assessment (FFR) and optical coherence tomography (OCT) systems will drive overall market growth, given their high demand, which is supported by clinical evidence needed to bring cost savings and improved outcomes. Physicians' preference for using noninvasive and minimally invasive diagnostic techniques in cases where results are inconclusive is also changing the landscape of innovation. In this feature, we'll take a closer look at the overall market and its regional perspective, the competitive landscape of the three fastest-growing segments ICE, FFR and OCT, and the latest emerging technologies, as well as provide insight into what physicians think of these technologies.

Cardiology Diagnostics

ABHI 2017: Hopes, Fears And Opportunities On UK Medtech Agenda

Securing market access at a time of an unprecedented budget squeeze, driving forward with medtech and digital innovation plans and maintaining barrier-free access to the EU market: these are the uppermost thoughts on the minds of UK medtech bosses. It's hard, but it's not mission impossible, industry and government leaders said at the ABHI's 2017 UK Market Conference.

United Kingdom Market Intelligence
See All

Appointments

Set Alert for Appointments

Latest From Appointments

Teamsters Ask Stockholders To Replace Cardinal Health Chairman

The International Brotherhood of Teamsters say that Cardinal Health CEO George Barrett failed to set the correct "tone at the top" while the firm became embroiled in the opioid epidemic and allegedly overpaid its chief compliance officer for illicit sales. The group is asking shareholders to appoint an independent board chairman, stripping Barrett of the role.

Commercial Appointments

Hannon Officially Takes The Helm At Mainstay Medical

Jason Hannon, former president and COO of spinal device manufacturer NuVasive Inc., has officially assumed the role of CEO and director of Irish company Mainstay Medical. He replaces Peter Crosby, who announced he would step down from the business in September.

Orthopedics Appointments

Physidia Brings Home New Blood

Home hemodialysis specialist Physidia has appointed a new company president to take the business to grow commercialization of its S3 device.

Renal Appointments
See All
UsernamePublicRestriction

Register